Press Releases

First Previous Next End

February 3, 2016

Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting

Provectus today announced data discussing the immunologic effects of PV-10 on colon cancer cells were presented yesterday at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

February 2, 2016

Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference

Provectus today announced that it will present at the 18th Annual BIO CEO & Investor Conference.

January 22, 2016

Provectus Biopharmaceuticals Announces Immunology Data on PV-10 in Colon Cancer to Be Presented at 11th Annual ASC Meeting

Provectus today announced that an abstract discussing the immunologic effects of PV-10 on colon cancer cells has been accepted for presentation at the 11th Annual Academic Surgical Congress to be held February 2-4, 2016, at the Hyatt Regency in Jacksonville, Florida.

January 12, 2016

Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma

Provectus today confirmed that patients have been dosed in both its Phase 3 clinical trial of PV-10, Provectus' novel investigational drug for cancer, for Stage III locally advanced cutaneous melanoma and its Phase 1b/2 clinical trial of PV-10 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with Stage IV melanoma. In addition, the Company confirmed that it continues to enroll patients in all of its active oncology studies.

December 16, 2015

Provectus Biopharmaceuticals, Inc. to Present at Biotech Showcase™ 2016 on Wednesday January 13, 2016 at 3:30 PM Pacific Time

Provectus today announced that it will present at Biotech Showcase™ 2016. The Company will summarize its business operations and discuss PV-10, its novel investigational drug for cancer, and PH-10, its topical investigational drug for dermatology.

November 5, 2015

Provectus Biopharmaceuticals Reports Immune Mechanism of Action Data for PV-10 Presented at Society for Immunotherapy of Cancer Annual Meeting Authored by Researchers at Moffitt Cancer Center

Provectus today announced that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1," at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland.

November 5, 2015

Provectus Biopharmaceuticals Reports Third Quarter 2015 Financial Results

Provectus today announced its results of operations and financial condition for the third quarter ended September 30, 2015.

October 20, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Third Quarter Business Update Conference Call on Thursday, November 5, 2015, at 5 PM Eastern Standard Time

Provectus announced today that it will hold its 2015 third quarter business update conference call at 5 pm Eastern Standard Time on Thursday, November 5, 2015.

September 29, 2015

Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation

Provectus today reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses."

September 23, 2015

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

Provectus today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.

September 21, 2015

Provectus Biopharmaceuticals Completes Patient Accrual for PH-10 Phase 2 Clinical Study of Cellular and Immunologic Changes in the Skin

Provectus today announced that it has completed patient accrual for its phase 2 study of the cellular and immunologic changes in the skin of patients receiving PH-10, an investigational topical treatment for atopic dermatitis and psoriasis.

August 18, 2015

Pfizer, Provectus Biopharmaceuticals Awarded US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer

Provectus today announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

August 6, 2015

Provectus Biopharmaceuticals Reports Second Quarter 2015 Financial Results

Provectus today announced its results of operations and financial condition for the second quarter ended June 30, 2015.

July 22, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Second Quarter Business Update Conference Call on Thursday, August 6, 2015, at 4 PM Eastern Daylight Time

Provectus announced today that it will hold its 2015 second quarter business update conference call at 4 pm Eastern Daylight Time on Thursday, August 6, 2015.

July 15, 2015

Provectus Biopharmaceuticals, Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search for Agreement on PV-10 Use in China

Provectus announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.

July 6, 2015

Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Provectus announced today that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.

July 2, 2015

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").

July 2, 2015

Provectus Biopharmaceuticals' Data on PV-10 for Chemoablation of Liver Cancers Presented at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).

June 26, 2015

AAPI Honors Provectus Biopharmaceuticals During 33rd Annual Convention and Scientific Assembly

The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.

June 26, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Treatment for Melanoma Presented at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

First Previous Next End